Frontier Medicines logo

Frontier Medicines

Emerging

Frontier Medicines is a precision medicine biotech targeting previously undruggable disease-causing proteins using chemoproteomics and covalent chemistry platforms; raised $350M+ in funding including a $257M Series C in 2022;

Best for: Precision Oncology & Undruggable Target Drug DiscoveryEmerging, rapid growth
Life Sciences & BioTechPrecision Oncology & Undruggable Target Drug DiscoveryWebsiteUpdated May 2026

Company Overview

About Frontier Medicines

Frontier Medicines is a South San Francisco-based biopharmaceutical company founded in 2018 by Ulf Bhatt and Jonathan Ogg, with scientific founding involvement from leading chemoproteomics researchers. The company's core focus is developing precision medicines against proteins that have historically been considered "undruggable" — disease-causing targets where conventional drug discovery approaches have failed due to the protein's structure, chemistry, or biology. Frontier addresses this challenge through two proprietary technology platforms: the Frontier platform (chemoproteomics-based covalent chemistry for small molecule drug discovery) and the AutoTAC platform (targeted protein degradation using autophagy pathways).

Business Model & Competitive Advantage

Frontier's chemoproteomics approach uses mass spectrometry-based proteomics to systematically profile reactive cysteines and other functional residues across thousands of proteins simultaneously — identifying novel binding pockets on target proteins that can be engaged by covalent small molecules. This enables the company to design drugs that bind irreversibly to previously inaccessible sites on oncoproteins, opening up targets like mutant KRAS (a driver in ~30% of all cancers), STAT3, and others that have resisted drug discovery efforts for decades. The AutoTAC platform extends this by designing molecules that recruit autophagy machinery to selectively degrade target proteins — a targeted protein degradation approach complementary to the more widely known PROTAC technology.

Competitive Landscape 2025–2026

Frontier Medicines raised over $350M in total funding, including a $257M Series C in 2022 led by Dragoneer Investment Group, with participation from Foresite Capital, GV (Google Ventures), and others. The company's clinical programs span multiple oncology indications targeting KRAS and other precision oncology drivers. Frontier competes in the precision oncology drug discovery space with companies like Revolution Medicines, Relay Therapeutics, and Recursion Pharmaceuticals, as well as Big Pharma oncology R&D divisions pursuing similar undruggable targets.

Founded
2018
Curated content • Fact-checked and verified

Key Differentiators

Emerging Innovator

Frontier Medicines is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.

Frequently Asked Questions

Similar Brands

Neuralink logo

Neuralink

Life Sciences & BioTech
HealthtechHardwareAi PoweredB2b2cStartupDecacornNorth AmericaTechnologyPlatformEnterprise

Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa

Pliant Therapeutics logo

Pliant Therapeutics

BioTech
HealthtechTechnologyPublicB2bStartup

Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero

BioNTech logo

BioNTech

Life Sciences & BioTech
B2bGlobalPublicEnterpriseHealthtechManufacturingPlatform

BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere

Illumina logo

Illumina

Life Sciences & BioTech
B2bGlobalPublicEnterpriseHealthtechAnalyticsHardwarePlatformFortune500

Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat

Cradle logo

Cradle

Life Sciences & BioTech
HealthtechSaasNorth AmericaB2b

Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti

Genentech logo

Genentech

Life Sciences & BioTech
B2bGlobalEnterprisePublicHealthtechManufacturingFortune500

Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching

For Frontier Medicines

Claim This Profile

Are you from Frontier Medicines? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim Frontier Medicines Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Frontier Medicines vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →